Shift Bioscience
Shift Bioscience is a biotech company uncovering the biology of cell rejuvenation to end the morbidity and mortality of aging. Its mission is to reduce cellular age without changing cell identity, developing the first drug pipeline validated for cellular age reversal in humans. Operating at the intersection of machine learning and cell biology, Shift’s AI-powered approach leverages virtual cell technology and large-scale, proprietary multiomic datasets to compress centuries of real-world experiments into months. The Company is progressing a pipeline of rejuvenation targets, initially targeting age-driven hearing loss, MASH and systemic sclerosis. Shift Bioscience was founded in 2017 by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO, with research facilities at the University of Cambridge, a computational group based in Toronto, Canada and a drug development team that brings experience from Alnylam, Moderna and GSK.Content by Shift Bioscience
| 2 min read
Well-calibrated metrics reveal that AI virtual cells can reliably identify biologically significant signals and accelerate target discovery pipelines.
Page 1 of 1 - 1 Total Items
